Efficacy and safety of 308‐nm excimer lamp in the treatment of scalp psoriasis: a retrospective study

2019 ◽  
Vol 35 (3) ◽  
pp. 172-177
Author(s):  
Ploysyne Rattanakaemakorn ◽  
Phanitchanat Phusuphitchayanan ◽  
Kallapan Pakornphadungsit ◽  
Kunlawat Thadanipon ◽  
Poonkiat Suchonwanit
Keyword(s):  
Retrospective Study ◽  
Efficacy And Safety ◽  
Excimer Lamp ◽  
Scalp Psoriasis

scholarly journals 308 nm excimer lamp in combination with topical tacrolimus: A retrospective study of its efficacy and safety in childhood vitiligo

2014 ◽  
Vol 15 (2) ◽  
pp. 74
Author(s):  
BS Chandrashekar ◽  
P Jagadish ◽  
ML Rajashekar ◽  
MA Sandeep ◽  
N Shobha ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Efficacy And Safety ◽  
Excimer Lamp ◽  
Topical Tacrolimus

scholarly journals The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study

2019 ◽  
Vol Volume 13 ◽  
pp. 3419-3424 ◽  
Author(s):  
Jiangtao Yu ◽  
Ziwen Xu ◽  
Anyang Li ◽  
Jindi Zhang ◽  
Yi Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Efficacy And Safety ◽  
Recurrent Cervical Cancer

scholarly journals Induction of labour in mid-trimester pregnancy using double-balloon catheter placement within 12 h versus within 12–24 h

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jing Peng ◽  
Ruobing Li ◽  
Shuguo Du ◽  
Heng Yin ◽  
Min Li ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Balloon Catheter ◽  
Induction Of Labour ◽  
Cervical Ripening ◽  
Efficacy And Safety ◽  
Research Subjects ◽  
Cervical Dilation ◽  
Double Balloon ◽  
Trimester Pregnancy ◽  
Vaginal Deliveries

Abstract Background This study aims to evaluate the efficacy and safety of the induction of labour in mid-trimester pregnancy using a double-balloon catheter (DBC) within 12 h versus within 12–24 h. Methods In this retrospective study, a total of 58 pregnant women at 14 + 0 weeks to 27 + 6 weeks of gestation were enrolled as research subjects, and they underwent the intended termination of pregnancy at our birth centre from January 1, 2017, to June 31, 2019. Based on the duration of DBC, the patients were divided into two groups, namely, the DBC group within 12 h and the DBC group within 12–24 h. Results All 58 cases were successful vaginal deliveries, and no one chose to undergo caesarean section. The success rate of induction (successful abortion of the foetus and placenta without the implementation of dilation and evacuation) was higher in the DBC group within 12–24 h (96.3%, 29/31) than in the DBC group within 12 h (71.0%, 18/27) (p < 0.05). Additionally, the time from DBC removal to delivery in the DBC group within 12–24 h was significantly shorter than that in the DBC group within 12 h (3.0 h versus 17.8 h) (p < 0.05), and the degree of cervical dilation after DBC removal in the DBC group within 12–24 h was larger than that in the DBC group within 12 h (p < 0.05). Conclusion In the clinic, the placement time of DBC generally lasts for approximately 12 h. However, considering that the cervical condition is immature in the mid-trimester, properly extending the placement time of DBC to 24 h will benefit cervical ripening and reduce the chance of dilation and evacuation.

scholarly journals AB0732 Efficacy and safety of rituximab in systemic sclerosis: french retrospective study and literature review

2018 ◽  
Author(s):  
M. Thiébaut ◽  
D. Launay ◽  
S. Rivière ◽  
T. Mahévas ◽  
S. Bellakhal ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Systemic Sclerosis ◽  
Literature Review ◽  
Efficacy And Safety

Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients

2016 ◽  
Vol 43 (8) ◽  
pp. 1547-1552 ◽  
Author(s):  
Alexis Régent ◽  
Serge Redeker ◽  
Alban Deroux ◽  
Pierre Kieffer ◽  
Kim Heang Ly ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Side Effects ◽  
Adverse Events ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Multicenter Study ◽  
Efficacy And Safety ◽  
Severe Adverse Events ◽  
Retrospective Multicenter Study

Objective.To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).Methods.A retrospective multicenter study that included 34 patients receiving TCZ for GCA.Results.TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months.Conclusion.TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.

Sign in / Sign up

Export Citation Format

Share Document